Quizartinib dihydrochloride is under clinical development by Daiichi Sankyo and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II drugs for Myeloproliferative Disorders have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Quizartinib dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Quizartinib dihydrochloride overview

Quizartinib dihydrochloride (Vanflyta) belongs to the class of phenylureas, with potential antineoplastic activity. It is formulated as film coated tablets for oral route of administration. Vanflyta is indicated for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).

Quizartinib dihydrochloride (AC220) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndrome, myeloproliferative neoplasm and chronic myelomonocytic leukemia. The drug candidate is administered orally as a tablet and intravenous route. It targets FMS-like tyrosine kinase 3 (FLT3). It is developed using KINOME scan technology. It was also under development for advanced solid tumors.

Daiichi Sankyo overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

For a complete picture of Quizartinib dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.